These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30922730)

  • 1. Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer.
    Konecny GE
    Lancet Oncol; 2019 May; 20(5):612-614. PubMed ID: 30922730
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival benefit with second-line combination in endometrial cancer.
    Romero D
    Nat Rev Clin Oncol; 2022 Mar; 19(3):149. PubMed ID: 35087212
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not.
    Paulino E
    Int J Gynecol Cancer; 2022 Apr; 32(4):579. PubMed ID: 35190462
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Kim J; Kim S; Lee HS; Yang W; Cho H; Chay DB; Cho SJ; Hong S; Kim JH
    Gynecol Oncol; 2018 May; 149(2):381-387. PubMed ID: 29572029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
    Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
    Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.
    Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
    Arch Gynecol Obstet; 2019 Aug; 300(2):377-382. PubMed ID: 31076855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
    Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
    J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.
    Pakish JB; Zhang Q; Chen Z; Liang H; Chisholm GB; Yuan Y; Mok SC; Broaddus RR; Lu KH; Yates MS
    Clin Cancer Res; 2017 Aug; 23(15):4473-4481. PubMed ID: 28264871
    [No Abstract]   [Full Text] [Related]  

  • 12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
    Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study.
    Giannice R; Erreni M; Allavena P; Buscaglia M; Tozzi R
    Cytokine; 2013 Nov; 64(2):509-15. PubMed ID: 23985752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
    Mehnert JM; Panda A; Zhong H; Hirshfield K; Damare S; Lane K; Sokol L; Stein MN; Rodriguez-Rodriquez L; Kaufman HL; Ali S; Ross JS; Pavlick DC; Bhanot G; White EP; DiPaola RS; Lovell A; Cheng J; Ganesan S
    J Clin Invest; 2016 Jun; 126(6):2334-40. PubMed ID: 27159395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer.
    Seki N; Kodama J; Hongo A; Miyagi Y; Yoshinouchi M; Kudo T
    Eur J Cancer; 2000 Jan; 36(1):68-73. PubMed ID: 10741297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
    Gong J; Wang C; Lee PP; Chu P; Fakih M
    J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of Mta-1 and VEGF and their correlation in the endometrial cancer].
    Yang YM; Liu H; Li WB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jul; 26(7):682-4. PubMed ID: 20619094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current recommendations and recent progress in endometrial cancer.
    Brooks RA; Fleming GF; Lastra RR; Lee NK; Moroney JW; Son CH; Tatebe K; Veneris JL
    CA Cancer J Clin; 2019 Jul; 69(4):258-279. PubMed ID: 31074865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.